FGF21 promotes angiotensin II-induced abdominal aortic aneurysm via PI3K/AKT/mTOR pathway

被引:0
|
作者
Gu, Xuefeng [1 ]
Li, Qi [1 ]
Qian, Tianwei [1 ]
Hu, Qi [1 ]
Gu, Jianfeng [1 ]
Ding, Wei [1 ]
Li, Ming [1 ]
Wang, Ming [1 ]
Lu, Huan [1 ]
Tao, Ke [1 ,2 ]
机构
[1] Soochow Univ, Changshu Hosp, Dept Gen Surg, Changshu, Peoples R China
[2] Soochow Univ, Changshu Hosp, 1 Shuyuan Rsd, Yushan Dist 215500, Changshu, Peoples R China
关键词
abdominal aortic aneurysm; FGF21; autophagy; PI3K; AKT; mTOR pathway; AUTOPHAGY; CELL; APOPTOSIS; GROWTH;
D O I
10.1177/17085381231192688
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Abdominal aortic aneurysm (AAA) is a potentially fatal vascular disorder with a high mortality rate. It was previously reported that fibroblast growth factor 21 (FGF21) was highly expressed in AAA patients. Nonetheless, its underlying mechanism in AAA progression is unclarified. Methods Angiotensin II (Ang-II) was used to induce AAA in human aortic vascular smooth muscle cells (HASMCs) and mouse models. Western blotting and RT-qPCR were utilized for measuring protein and RNA levels. Immunofluorescence staining was utilized for detecting LC3B expression in HASMCs. Elastica van Gieson staining was conducted for histological analysis of the abdominal aortas of mice. Results FGF21 displayed a high level in Ang-II-stimulated HASMCs and AAA mice. FGF21 depletion ameliorated abdominal aorta dilation and Ang-II-triggered pathological changes in mice. FGF21 silencing hindered autophagy and PI3K/AKT/mTOR pathway. Conclusions FGF21 contributes to AAA progression by enhancing autophagy and activating PI3K/AKT/mTOR pathway.
引用
收藏
页码:1369 / 1377
页数:9
相关论文
共 50 条
  • [41] FGF21 promotes non-small cell lung cancer progression by SIRT1/PI3K/AKT signaling
    Yu, Xiaofeng
    Li, Ying
    Jiang, Guodong
    Fang, Jian
    You, Zhaolei
    Shao, Guangyuan
    Zhang, Zheng
    Jiao, Aihong
    Peng, Xiaonu
    LIFE SCIENCES, 2021, 269
  • [42] Oxidative stress induced by combined glyphosate and TBBPA exposure promotes gill autophagy and inflammation via the PI3K/AKT/ mTOR pathway
    Li, Mingyue
    Lou, Shuang
    Chen, Kai
    Dong, Yuting
    Wang, Shize
    Yu, Tingting
    Deng, Xinrui
    Li, Shu
    FISH & SHELLFISH IMMUNOLOGY, 2025, 160
  • [43] Targeting the PI3K/Akt/mTOR Pathway in Ocular Neovascularization
    Sasore, Temitope
    Reynolds, Alison L.
    Kennedy, Breandan N.
    RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY, 2014, 801 : 805 - 811
  • [44] Tolvaptan reduces angiotensin II-induced experimental abdominal aortic aneurysm and dissection
    Wu, Tao-Cheng
    Chang, Wei-Hung
    Lu, Hsin-Ying
    Shih, Chun-Che
    VASCULAR PHARMACOLOGY, 2022, 144
  • [45] Deficiency of peroxiredoxin 2 exacerbates angiotensin II-induced abdominal aortic aneurysm
    Se-Jin Jeong
    Min Ji Cho
    Na Young Ko
    Sinai Kim
    In-Hyuk Jung
    Jeong-Ki Min
    Sang Hak Lee
    Jong-Gil Park
    Goo Taeg Oh
    Experimental & Molecular Medicine, 2020, 52 : 1587 - 1601
  • [46] Tollip promotes hepatocellular carcinoma progression via PI3K/AKT pathway
    Huang, Lu
    Yang, Qiong
    Chen, Huihong
    Wang, Zhenggeng
    Liu, Qi
    Ai, Shuhua
    OPEN MEDICINE, 2022, 17 (01): : 626 - 637
  • [47] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
    Barra, Fabio
    Desideri, Lorenzo Ferro
    Ferrero, Simone
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3626 - 3627
  • [48] Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
    LoRusso, Patricia Mucci
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3803 - +
  • [49] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 335 - 342
  • [50] Evaluation of the PI3K/AKT/mTOR pathway in multiple sclerosis
    Mammana, Santa
    Fagone, Paolo
    Cavalli, Eugenio
    Basile, Maria Sofia
    Petralia, Maria Cristina
    Nicoletti, Ferdinando
    Mangano, Katia
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S51 - S51